A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.
Relapsed Ewing Sarcoma
DRUG: INCB059872
Number of adverse events, Defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of a drug in humans, whether or not considered drug-related., Screening through 30 days after last dose of study treatment, up to approximately 6 months.
Objective response rate, Defined as the percentage of participants who have a complete response or partial response as determined by investigator assessment of response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1., Up to approximately 6 months.|Cmax of INCB059872, Defined as maximum observed plasma concentration., Up to approximately 2 weeks.|tmax of INCB059872, Defined as time to maximum concentration., Up to approximately 2 weeks.|tÂ½ of INCB059872, Defined as apparent terminal-phase disposition half-life., Up to approximately 2 weeks.|Cl/F of INCB059872, Defined as apparent oral dose clearance., Up to approximately 2 weeks.
The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.